Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Mallinckrodt
AstraZeneca
Johnson and Johnson
McKesson

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206829

See Plans and Pricing

« Back to Dashboard

NDA 206829 describes ZERBAXA, which is a drug marketed by Cubist Pharms Llc and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug. Additional details are available on the ZERBAXA profile page.

The generic ingredient in ZERBAXA is ceftolozane sulfate; tazobactam sodium. One supplier is listed for this compound. Additional details are available on the ceftolozane sulfate; tazobactam sodium profile page.
Summary for 206829
Tradename:ZERBAXA
Applicant:Cubist Pharms Llc
Ingredient:ceftolozane sulfate; tazobactam sodium
Patents:11
Generic Entry Opportunity Date for 206829
Generic Entry Date for 206829*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 206829
Mechanism of Actionbeta Lactamase Inhibitors
Suppliers and Packaging for NDA: 206829
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829 NDA Merck Sharp & Dohme Corp. 67919-030 67919-030-01 10 VIAL, SINGLE-DOSE in 1 CARTON (67919-030-01) > 10 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAVENOUSStrengthEQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL
Approval Date:Dec 19, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 19, 2024
Regulatory Exclusivity Use:GENERATING ANTIBIOTIC INCENTIVES NOW
Regulatory Exclusivity Expiration:Dec 19, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:  Start TrialPatent Expiration:Sep 7, 2032Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Medtronic
Johnson and Johnson
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.